Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 234 participants.
Also called NCT07840365
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 234 participants
- Registry
-
NCT07840365
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07840365. Randomized; no masking; primary purpose prevention. Start 2026-09-01 (actual); primary completion 2028-12-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion
- Acronym
- INTEGRAL
- Condition
- Atrial Fibrillation (AF)
- Intervention (Drug)
- Half-Dose of novel OAC
- Intervention (Drug)
- Low-dose ASA
- Lead sponsor
- Texas Cardiac Arrhythmia Research Foundation
Record details
- Record id
cardio:ct-nct07840365- Content hash
460c1402935fb22d94b6a59dd937848de29db1df32f72faf49ae30c3b57b88d5